Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating Expenses:        
Research and development expenses $ 1,691,688 $ 1,847,178 $ 6,062,360 $ 3,789,800
General and administrative expenses 2,371,840 1,491,173 7,245,227 3,667,588
Total Operating Expenses 4,063,528 3,338,351 13,307,587 7,457,388
Loss From Operations (4,063,528) (3,338,351) (13,307,587) (7,457,388)
Other Income (Expense)        
Interest income 2,862 2,532 4,338 31,146
Change in value of contingent liability (274,524) (335,727)
Other income 17,406   46,494 2,500
Total other income (expense) (254,256) 2,532 (284,895) 33,646
Loss Before Provision For Income Taxes (4,317,784) (3,335,819) (13,592,482) (7,423,742)
Provision for income taxes
Net Loss $ (4,317,784) $ (3,335,819) $ (13,592,482) $ (7,423,742)
Net loss per share, basic and diluted (in Dollars per share) $ (0.22) $ (0.24) $ (0.76) $ (0.63)
Weighted average shares, basic and diluted (in Shares) 19,848,108 13,646,153 17,864,604 11,825,179